Affordable Access

deepdyve-link
Publisher Website

Incidence of inter-attack asymptomatic brain lesions in NMO spectrum disorder.

Authors
  • Lee, Min Young1
  • Yong, Kok Pin2
  • Hyun, Jae-Won1
  • Kim, Su-Hyun3
  • Lee, Sang-Hyun4
  • Kim, Ho Jin3
  • 1 Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. , (North Korea)
  • 2 Department of Neurology, National Neuroscience Institute, Singapore. , (Singapore)
  • 3 Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea [email protected] , (North Korea)
  • 4 Department of Radiology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. , (North Korea)
Type
Published Article
Journal
Neurology
Publisher
Ovid Technologies (Wolters Kluwer) - American Academy of Neurology
Publication Date
Sep 14, 2020
Identifiers
DOI: 10.1212/WNL.0000000000010847
PMID: 32928976
Source
Medline
Language
English
License
Unknown

Abstract

To determine whether aquaporin-4 (AQP4) antibody seropositive patients with neuromyelitis optica spectrum disorder (NMOSD) develop new asymptomatic brain lesions during the inter-attack period. Of 296 consecutive patients with AQP4 antibody seropositive in the NMOSD database of National Cancer Center from May 2005 to November 2019, 145 patients, who had serial brain MRI scans over an interval of at least 1 year during relapse-free period after immunosuppressive therapy, with 370 longitudinally assessed brain MRI scans were included in this study. We retrospectively analyzed them for presence of new subclinical brain lesions during the relapse-free period. Five (3.4%) of 145 patients had detectable new, asymptomatic brain lesions in the deep white matter over a total observed relapse-free period of 708 person-years. All the lesions were less than 6 mm in size and assessed to be non-specific. No brain lesion characteristic of NMOSD or gadolinium-enhancing lesion was identified. Asymptomatic brain lesions are rarely observed on conventional MRI in clinically stable AQP4 antibody seropositive patients with NMOSD after immunosuppressive therapy and brain MRI lesions characteristic of NMOSD are not seen in the relapse-free period. These findings may provide further insight regarding currently known diagnostic and disease monitoring strategies in NMOSD. © 2020 American Academy of Neurology.

Report this publication

Statistics

Seen <100 times